SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (2763)11/15/2019 12:15:52 PM
From: Miljenko Zuanic  Respond to of 3557
 
RE:KOD

Kodiak S. continue with strong up-trajectory. Per 3Qcc, their plan for 301 BLA (or pivotal trials) is first two CRVO/BRVO (6 -months end-point) than AMD/DME sBLA from combine AMD/DME pivotal results.

While RVO P1b data point to strong (+20 letters gain on BCVA, 12-20w), first week jump of +12 letter is REAL SCIENCE-FICTION! (slide 28).
So, I continue to be *suspicious* about potency of the KSI-301.